MedTrace Logo

Addition of Naltrexone to Methadone Taper

NCT00135759 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2017-01-12

No results posted yet for this study

Summary

There is a continuing search for more effective opiate detoxification treatments. This study's purpose is to investigate the effects of adding very low doses of naltrexone to a methadone tapering treatment in opioid dependent individuals.

Conditions

  • Heroin Dependence
  • Opioid-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

Naltrexone

low dose naltrexone in addition to daily methadone taper

DRUG

Placebo comparator

1 capsule/day for 6 days

DRUG

naltrexone

0.125 mg capsule/day for 6 days

DRUG

naltrexone

0.250 mg capsule/day for 6 days

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Paolo Mannelli, M.D. · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00135759 on ClinicalTrials.gov